Table 3 The pharmacokinetic parameters of rapamycin in mouse whole blood and pulmonary interstitial fluid (PIF) after oral (P.O.) or intervaginal space injection (ISI) administration
From: Rapamycin nanoparticles improves drug bioavailability in PLAM treatment by interstitial injection
p.o.PIF | isi.PIF | p.o.blood | isi.blood | |
|---|---|---|---|---|
Tmax (h) | 1.33 ± 0.47 | 1.33 ± 0.47 | 1.67 ± 1.15 | 1.00 ± 0.00 |
Cmax (µg/g or µg/mL) | 1.43 ± 0.66 | 6.84 ± 0.86 | 0.40 ± 0.09 | 4.74 ± 0.21 |
AUC0→72 h (h * µg/g or h * µg/mL) | 5.30 ± 1.80 | 47.44 ± 4.51 | 1.61 ± 0.38 | 51.48 ± 6.79 |
AUC0→∞ (h * µg/g or h*µg/mL) | 5.46 ± 1.84 | 48.87 ± 4.91 | 1.69 ± 0.42 | 52.16 ± 6.98 |
CL (103 * g/h/kg or 103 * ml/h/kg) | 19.77 ± 8.37 | 2.07 ± 0.22 | 62.45 ± 13.29 | 1.95 ± 0.24 |
F (Fisi/Fp.o.) | 9.83 ± 4.62 | 31.70 ± 3.65 |